Adropin intervention was reported to prevent hyperglycemia and hyperlipidemia; improve glucose tolerance; increase whole-body insulin sensitivity; inhibit hepatic glucose production; ameliorate hepatic insulin sensitivity; decrease cardiac glucose oxidation and cardiac pyruvate dehydrogenase activity; reduce serum levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, AST, ALT, alkaline phosphatase, and GGT; and increase the level of high-density lipoprotein cholesterol. The gene discussed is INS; the disease is Hyperglycemia.